Overview
IMRX market data
Price History
IMRX price chart · 3M
- O
- 4.99
- H
- 4.99
- L
- 4.81
- C
- 4.82
- Vol
- 55,448.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $4.99
- Previous Close
- $5.04
- Day High
- $4.99
- Day Low
- $4.81
- 52 Week High
- $6.89
- 52 Week Low
- $3.90
- 7 Day Return
- -3.41%
- 30 Day Return
- +10.30%
- 90 Day Return
- +22.96%
- 1 Year Return
- -7.31%
- Daily Notional Volume
- $267.3K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.03 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.34 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -9,610.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $3.86 – $10.08 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $311.8M · P/B 1.94 · P/S 623.68.
Company News
10 captured
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line PatientsGlobenewswire Inc ·
HC Wainwright & Co. Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $14Benzinga ·
8-K filing — Immuneering Corp (IMRX)SEC EDGAR ·
Immuneering Q2 EPS $(0.27), InlineBenzinga ·